Triptorelin / Decapeptyl / Trelstar - Debiopharm

Home » Media » Publications

Triptorelin / Decapeptyl / Trelstar

Date	Article Title
01 Dec 2009	Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer
31 Jul 2003	Comparative Efficacy of Triptorelin Pamoate and Leuprolide Acetate in Men with Advanced Prostate Cancer
30 Dec 2001	A phase II trial with New Triptorelin Sustained Release formulations in Prostatic Carcinoma
30 Dec 2000	Effects of an extended-interval Dosing Regimen of Triptorelin Depot on the Hormonal Profile of Patients with Endometriosis (prospective observational study)
30 Dec 2000	A Crossover Study of Triptorelin and Leuprorelin Acetate
30 May 1999	Effectiveness and Tolerance of one dosage form (subcutaneous and intramuscular) of Decapeptyl Depot
30 Dec 1998	Three-month sustained-release form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma

Latest News

15 May 2012 Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland - A drug treatment for prostate cancer and endometriosis

16 February 2012 Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

09 November 2011 Augurix Diagnostics receives the 2011 ‘Debiopharm /Valais Award’ For its point-of-care diagnostic test for the early detection of Celiac disease

Debiopharm on

© 2012 Debiopharm Group